Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 16/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 16/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628795 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL8706893 | 0.86 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL8705978 | 0.83 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL5618524 | 0.82 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL8709974 | 0.82 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL14159752 | 0.82 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL14270472 | 0.81 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL8705885 | 0.78 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL6247693 | 0.74 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 | |
| SCHEMBL6640436 | 0.74 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1196167-B1 | Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions | LIPTON STUART A (US) | 2006-04-19 | — | — | EP | claimed |
| US-20030078274-A1 | Method of reducing neuronal injury or apoptosis | LIPTON STUART A (US) | 2003-04-24 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-10441577-B2 | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) | 2019-10-15 | — | — | US | disclosed |
| US-10010536-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9527816-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| EP-2591784-B1 | Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system | INTERMUNE INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070128719-A1 | ISOLATION AND EXPANSION OF ANIMAL CELLS IN CELL CULTURES | TISSUETECH, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070128719-A1 | ISOLATION AND EXPANSION OF ANIMAL CELLS IN CELL CULTURES | TISSUETECH, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1196167-B1 | Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions | LIPTON STUART A (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1196167-A4 | METHOD OF REDUCING NEURONAL INJURY OR APOPTOSIS | LIPTON STUART A (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030078274-A1 | Method of reducing neuronal injury or apoptosis | LIPTON STUART A (US) | 2003-04-24 | — | — | US | disclosed |
| EP-1196167-A1 | METHOD OF REDUCING NEURONAL INJURY OR APOPTOSIS | Lipton, Stuart A. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001035959-A1 | USE OF THIAZOLE DERIVATIVES FOR TREATMENT/PREVENTION OF P38 KINASE MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001001986-A1 | METHOD OF REDUCING NEURONAL INJURY OR APOPTOSIS | LIPTON STUART A (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078274-A1 | Method of reducing neuronal injury or apoptosis | GAP43, DCX, NLN | MAPK14 40/4885MAPK13 129/4885MAPK12 42/4885 |
| US-10010536-B2 | Method of modulating stress-activated protein kinase system | MAPKAPK2, MAP3K6, MAP4K1 | MAPK14 36/4885MAPK13 37/4885MAPK12 39/4885 |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | MAPK14 36/4885MAPK13 37/4885MAPK12 39/4885 |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | MAPK14 636/4885MAPK13 715/4885MAPK12 797/4885 |
| US-10441577-B2 | Medicament for treatment of liver cancer | PYGL, PFKL, GLS2 | MAPK14 523/4885MAPK13 685/4885MAPK12 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.